{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:10:39Z","timestamp":1791612639471,"version":"4.3.4"},"reference-count":83,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Primary membranous nephropathy (PMN) is considered a major cause of nephrotic syndrome. The discovery of circulating autoantibodies directed against glomerular podocytes helped to classify them as autoimmune diseases. Over the past years, there has been an increasing significance of anti-Phospholipase A2 Receptor (anti-PLA2R), which has been detected in 70\u201380% of PMN cases, and relevance of anti-Thrombospondin type I domain-containing 7A (anti-THSD7A) even though they are present in 2\u20135% of patients. The results of clinical and experimental studies indicate that these antibodies are pathogenic. It radically changed the diagnostic and therapeutic approach. Measurement of antibody titers in the serum seems to be a valuable tool for identifying PMN and for the assessment of disease activity. By monitoring pathogenic antibodies levels rather than proteinuria or reduced glomerular filtration rate (GFR) as an indicator of glomerular disease, physicians would easier divide patients into those with active and inactive PMN disease and decide about their therapy. The aim of this review is to evaluate scientific evidence about the role of autoantibodies, namely anti-PLA2R and anti-THSD7A, as PMN biomarkers. The present manuscript focuses on PMN pathogenesis and key data of diagnosis, monitoring of the disease, and treatment strategies that are currently being used in clinical practice.<\/jats:p>","DOI":"10.3390\/ijerph19095301","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T13:40:57Z","timestamp":1651066857000},"page":"5301","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Role of Anti-PLA2R and Anti-THSD7A Antibodies in the Pathogenesis and Diagnostics of Primary Membranous Nephropathy: A Review of Current Knowledge for Clinical Practice"],"prefix":"10.3390","volume":"19","author":[{"given":"Iwona","family":"Smarz-Widelska","sequence":"first","affiliation":[{"name":"Department of Nephrology, Cardinal Stefan Wyszynski Provincial Hospital, 20-718 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Choj\u0119ta","sequence":"additional","affiliation":[{"name":"Chair and Department of Medical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-8594","authenticated-orcid":false,"given":"Ma\u0142gorzata M.","family":"Kozio\u0142","sequence":"additional","affiliation":[{"name":"Chair and Department of Medical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: Membranous nephropathy\u2014A modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-pathol-020117-043811","article-title":"Molecular Pathogenesis of Membranous Nephropathy","volume":"15","author":"Ronco","year":"2020","journal-title":"Annu. Rev. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_4","first-page":"62","article-title":"Pierwotna nefropatia b\u0142oniasta. Patofizjologia, morfologia oraz zalecenia dotycz\u0105ce diagnostyki i leczenia","volume":"20","author":"Karkosza","year":"2016","journal-title":"Nefrol. Dial. Pol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Trachtman, H., Herlitz, L., Lerma, E., and Hogan, J. (2019). PLA2R- and THSD7A-Associated Primary Membranous Nephropathy. Glomerulonephritis, Springer.","DOI":"10.1007\/978-3-319-49379-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"64","article-title":"Secondary membranous glomerulonephritis","volume":"7","author":"Glassock","year":"1992","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: From models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6281054","DOI":"10.1155\/2018\/6281054","article-title":"Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management","volume":"2018","author":"Pozdzik","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.2004121080","article-title":"Molecular pathomechanisms of membranous nephropathy: From heymann nephritis to alloimmunization","volume":"16","author":"Ronco","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fimmu.2016.00157","article-title":"Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy","volume":"7","author":"Borza","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e140453","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nm0395-237","article-title":"Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein","volume":"1","author":"Malhotra","year":"1995","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e122399","DOI":"10.1172\/jci.insight.122399","article-title":"Tubular injury triggers podocyte dysfunction by \u03b2-catenin-driven release of MMP-7","volume":"4","author":"Tan","year":"2019","journal-title":"JCI Insight"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI58552","article-title":"CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival","volume":"121","author":"Yaddanapudi","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1172\/JCI32022","article-title":"Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease","volume":"117","author":"Sever","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fmed.2018.00221","article-title":"Proteinuric Kidney Diseases: A Podocyte\u2019s Slit Diaphragm and Cytoskeleton Approach","volume":"5","author":"Yu","year":"2018","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: What we know and what remains a decade after its discovery","volume":"96","author":"Fresquet","year":"2019","journal-title":"Kidney Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102308","DOI":"10.1016\/j.jaut.2019.102308","article-title":"Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain","volume":"106","author":"Fresquet","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-017-0451-5","article-title":"Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases","volume":"31","author":"Radice","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/nep.12997","article-title":"Anti-PLA2R antibody in a secondary cause of membranous nephropathy","volume":"23","author":"Kumar","year":"2018","journal-title":"Nephrology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfr534","article-title":"Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy","volume":"27","author":"Qu","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cca.2018.06.050","article-title":"Clinical and prognostic significance of glomerular C1q deposits in primary MN","volume":"485","author":"Zhang","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.kint.2015.12.057","article-title":"Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis","volume":"89","author":"Ryan","year":"2016","journal-title":"Kidney Int."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"KDIGO Clinical Practice Guideline for Glomerulonephritis (2012). Chapter 7: Idiopathic membranous nephropathy. Kidney Int. Suppl., 2, 186\u2013197.","DOI":"10.1038\/kisup.2012.20"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A Proposal for a Serology-Based Approach to Membranous Nephropathy","volume":"28","author":"Glassock","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin Type 1 Domain-Containing 7A Localizes to the Slit Diaphragm and Stabilizes Membrane Dynamics of Fully Differentiated Podocytes","volume":"30","author":"Herwig","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A Mechanism for Cancer-Associated Membranous Nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Taguchi, S., Koshikawa, Y., Ohyama, S., Miyachi, H., Ozawa, H., and Asada, H. (2019). Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: A case report. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1236-y"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.ajkd.2018.10.009","article-title":"VEGF-A Links Angiolymphoid Hyperplasia with Eosinophilia (ALHE) to THSD7A Membranous Nephropathy: A Report of 2 Cases","volume":"73","author":"Matsumoto","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2169\/internalmedicine.54.4031","article-title":"Observation of Angiolymphoid Hyperplasia with Eosinophilia (ALHE) at Three Arterial Sites and Its Association with Membranous Nephropathy","volume":"54","author":"Ito","year":"2015","journal-title":"Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Xian, L., Dong, D., Luo, J., Zhuo, L., Li, K., Zhang, P., Wang, W., Xu, Y., Xu, G., and Wang, L. (2019). Expression of THSD7A in neoplasm tissues and its relationship with proteinuria. BMC Nephrol., 20.","DOI":"10.1186\/s12882-019-1489-5"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00428-019-02558-0","article-title":"Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy","volume":"474","author":"Hara","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11255-018-02068-z","article-title":"THSD7A as a marker for paraneoplastic membranous nephropathy","volume":"51","author":"Wang","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Iwakura, T., Ohashi, N., Kato, A., Baba, S., and Yasuda, H. (2015). Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138841"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ekir.2017.09.009","article-title":"Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy","volume":"3","author":"Berchtold","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2215\/CJN.01460217","article-title":"Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy","volume":"12","author":"Wang","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_49","first-page":"171","article-title":"Preliminary results of research on a new marker of idiopathic membranous nephropathy: Anti-PLA2R","volume":"36","author":"Sikora","year":"2014","journal-title":"Pol. Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Maifata, S.M., Hod, R., Zakaria, F., and Abd Ghani, F. (2019). Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management. Biomedicines, 7.","DOI":"10.20944\/preprints201909.0218.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cca.2018.12.027","article-title":"Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy: Clinical value assessment","volume":"490","author":"Cheng","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-Phospholipase A2 Receptor Antibody in Membranous Nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s11255-016-1263-6","article-title":"The accuracy of the anti-phospholipase A2 receptor antibody in the diagnosis of idiopathic membranous nephropathy: A comparison of different cutoff values as measured by the ELISA method","volume":"48","author":"Dou","year":"2016","journal-title":"Int. Urol. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cca.2017.11.006","article-title":"Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients","volume":"476","author":"Liu","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40620-018-0533-z","article-title":"Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy","volume":"31","author":"Tampoia","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2215\/CJN.05880614","article-title":"Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: A new personalized medical approach","volume":"9","author":"Glassock","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000481635","article-title":"Membranous Nephropathy: Approaches to Treatment","volume":"47","author":"Bomback","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.23876\/j.krcp.2018.37.3.248","article-title":"Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy","volume":"37","author":"Song","year":"2018","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pourcine, F., Dahan, K., Mihout, F., Cachanado, M., Brocheriou, I., Debiec, H., and Ronco, P. (2017). Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0173201"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s11255-019-02146-w","article-title":"Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy","volume":"51","author":"Tian","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/IJNRD.S176665","article-title":"Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults","volume":"11","author":"Wu","year":"2018","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"ref_65","first-page":"1825","article-title":"Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy","volume":"17","author":"Han","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000494662","article-title":"Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy","volume":"48","author":"Qu","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: Integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: Time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_74","first-page":"350","article-title":"Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis after Kidney Transplant Refractory to Combined Conventional Rituximab Therapy","volume":"15","author":"Barbari","year":"2017","journal-title":"Exp. Clin. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent Membranous Nephropathy after Kidney Transplantation: Treatment and Long-Term Implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2013.07.004","article-title":"Recurrence of glomerulonephritis after renal transplantation","volume":"27","author":"Sprangers","year":"2013","journal-title":"Transplant. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/TP.0000000000000630","article-title":"Antiphospholipase A2 Receptor Antibody Levels Predict the Risk of Posttransplantation Recurrence of Membranous Nephropathy","volume":"99","author":"Quintana","year":"2015","journal-title":"Transplantation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5500\/wjt.v12.i1.15","article-title":"Is de novo membranous nephropathy suggestive of alloimmunity in renal transplantation? A case report","volume":"12","author":"Darji","year":"2022","journal-title":"World J. Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3389\/fimmu.2019.01326","article-title":"Membranous Nephropathy (MN) Recurrence after Renal Transplantation","volume":"10","author":"Passerini","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1600-6143.2011.03957.x","article-title":"Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation","volume":"12","author":"Blosser","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1111\/j.1600-6143.2011.03643.x","article-title":"Autoantibodies specific for the phospholipase A2 receptor in recurrent and de novo membranous nephropathy","volume":"11","author":"Debiec","year":"2011","journal-title":"Am. J. Transplant."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/9\/5301\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:01:46Z","timestamp":1760137306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/9\/5301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":83,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijerph19095301"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19095301","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}